Merck & Co licenses Isis drug
Isi Pharmaceuticals has licensed its preclinical Type II diabetes antisense drug candidate ISIS 113715 to Merck & Co. Preclinical data demonstrate activity in animal models of Type II diabetes.
Isi Pharmaceuticals has licensed its preclinical Type II diabetes antisense drug candidate ISIS 113715 to Merck & Co. Preclinical data demonstrate activity in animal models of Type II diabetes.